GI-101

GI-101 is a novel bispecific recombinant fusion protein designed for cancer immunotherapy. It consists of the extracellular domain of cluster of differentiation 80 (CD80) fused to an interleukin-2 variant (IL-2v), both conjugated with a human IgG4 Fc fragment. The drug is engineered to stimulate immune cell proliferation and activation, particularly cytotoxic T lymphocytes and natural killer (NK) cells, by engaging both the CD28 co-stimulatory pathway and IL-2 receptor signaling. This dual mechanism aims to enhance anti-tumor immunity while potentially overcoming resistance seen with standard PD-1/PD-L1 checkpoint inhibitors. GI-101 is being developed primarily for advanced solid tumors and hematological malignancies as monotherapy or in combination with other agents such as pembrolizumab, lenvatinib, or radiotherapy[1][3][4][5][6][7][8].